Experts say acquisitions, not Congress, will chart biotech’s course in 2020

Experts say acquisitions, not Congress, will chart biotech’s course in 2020

STAT Plus: Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict 

By KATE SHERIDAN

MICHELLE CLAIRE GEVINT FOR STAT

Three investors told STAT what they're expecting to drive the most change for the biotech industry in 2020, from politics to acquisitions.

READ MORE